{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:16:28Z","timestamp":1781558188175,"version":"3.54.5"},"reference-count":141,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cllc.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:57:47Z","timestamp":1718233067000},"page":"483-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5830-1475","authenticated-orcid":false,"given":"Xiancheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura P.","family":"Stabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-3762","authenticated-orcid":false,"given":"Timothy F.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cllc.2024.06.004_bib0001","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2024.06.004_bib0005","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2024.06.004_bib0006","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0008","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2024.06.004_bib0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.004_bib0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.004_bib0011","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"},{"issue":"42","key":"10.1016\/j.cllc.2024.06.004_bib0012","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/EDBK_349155","article-title":"Extending our reach: expanding enrollment in brain metastases and primary brain tumor clinical trials","author":"Lee","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.004_bib0013","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The Microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0014","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","article-title":"The seed and soil hypothesis: vascularisation and brain metastases","volume":"3","author":"Fidler","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3389\/fimmu.2019.01713","article-title":"Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis","volume":"10","author":"Schulz","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.cllc.2024.06.004_bib0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.nurt.2010.07.006","article-title":"Functions of astrocytes and their potential as therapeutic targets","volume":"7","author":"Kimelberg","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0017","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","article-title":"Serpins promote cancer cell survival and vascular co-option in brain metastasis","volume":"156","author":"Valiente","year":"2014","journal-title":"Cell"},{"issue":"7604","key":"10.1016\/j.cllc.2024.06.004_bib0018","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature18268","article-title":"Carcinoma\u2013astrocyte gap junctions promote brain metastasis by cGAMP transfer","volume":"533","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"7576","key":"10.1016\/j.cllc.2024.06.004_bib0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature15376","article-title":"Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth","volume":"527","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.004_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/0008-5472.CAN-18-1805","article-title":"A blazing landscape: neuroinflammation shapes brain metastasis","volume":"79","author":"Doron","year":"2019","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0021","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","article-title":"STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis","volume":"24","author":"Priego","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.14336\/AD.2023.0514","article-title":"The role of microglia in brain metastases: mechanisms and strategies","volume":"15","author":"Feng","year":"2023","journal-title":"Aging Dis"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.004_bib0023","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2024.06.004_bib0024","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2021.12.043","article-title":"Cellular architecture of human brain metastases","volume":"185","author":"Gonzalez","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0026","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/1078-0432.CCR-19-2184","article-title":"Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival","volume":"26","author":"Pocha","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0027","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0028","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.cllc.2024.06.004_bib0029","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.004_bib0030","doi-asserted-by":"crossref","first-page":"e1101","DOI":"10.1002\/ctm2.1101","article-title":"Single-cell RNA sequencing reveals cellular and molecular reprograming landscape of gliomas and lung cancer brain metastases","volume":"12","author":"Sun","year":"2022","journal-title":"Clin Transl Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0031","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3171\/2016.8.JNS16899","article-title":"Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis","volume":"127","author":"Mitsuya","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.cllc.2024.06.004_bib0032","doi-asserted-by":"crossref","first-page":"38585","DOI":"10.1038\/srep38585","article-title":"Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer","volume":"6","author":"Koh","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0033","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-21-1130","article-title":"B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy?","volume":"28","author":"Lauss","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.06.004_bib0034","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fonc.2017.00115","article-title":"Mast cell infiltration in human brain metastases modulates the microenvironment and contributes to the metastatic potential","volume":"7","author":"Roy","year":"2017","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2024.06.004_bib0036","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","article-title":"Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0037","doi-asserted-by":"crossref","first-page":"iv465","DOI":"10.1093\/annonc\/mdu349.103","article-title":"1324P - tumor-infiltrating lymphocytes (tils) and Pd-L1 expression in non- small cell lung cancer brain metastases (bm) and matched primary tumors (pt)","volume":"25","author":"Berghoff","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0038","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1038\/s41467-022-33365-y","article-title":"The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2059874","article-title":"Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)","volume":"11","author":"Li","year":"2022","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1016\/j.cllc.2024.06.004_bib0040","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0041","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cllc.2024.06.004_bib0042","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2024.06.004_bib0043","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.cllc.2024.06.004_bib0044","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.cllc.2024.06.004_bib0046","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0047","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.004_bib0048","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-Ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0049","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cllc.2021.02.001","article-title":"Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (\u2265 50%) NSCLC: real-world results with special focus on PS \u2265 2, brain metastases, and steroids","volume":"22","author":"Frost","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","article-title":"Outcomes in patients with non-small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy","volume":"22","author":"Sun","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0051","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0052","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CJI.0000000000000340","article-title":"Efficacy of pembrolizumab monotherapy in patients with or without brain metastases from advanced non-small cell lung cancer with a PD-L1 expression \u226550%","volume":"43","author":"Metro","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.cllc.2024.06.004_bib0053","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2020.11.009","article-title":"Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression","volume":"151","author":"Wakuda","year":"2021","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0054","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2024.06.004_bib0055","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jtho.2016.08.107","article-title":"P2.36: nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets): track: immunotherapy","volume":"11","author":"Goldman","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0056","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crin\u00f2","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.06.004_bib0057","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.011","article-title":"Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer","volume":"123","author":"Grossi","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.004_bib0058","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.21873\/anticanres.13590","article-title":"Italian cohort of the nivolumab EAP in squamous NSCLC: efficacy and safety in patients with CNS metastases","volume":"39","author":"Cortinovis","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2024.06.004_bib0059","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","article-title":"Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases","volume":"116","author":"Gauvain","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.06.004_bib0060","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920967237","article-title":"Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)","volume":"12","author":"Assi\u00e9","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0061","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2021.04.022","article-title":"Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada","volume":"157","author":"Debieuvre","year":"2021","journal-title":"Lung Cancer"},{"issue":"10274","key":"10.1016\/j.cllc.2024.06.004_bib0062","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2024.06.004_bib0063","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.004_bib0064","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jtho.2018.05.004","article-title":"FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with NSCLC","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non\u2013small cell lung cancer: the MYSTIC phase 3 randomized clinical Trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.cllc.2024.06.004_bib0066","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2024.06.004_bib0067","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_Supplement","key":"10.1016\/j.cllc.2024.06.004_bib0068","doi-asserted-by":"crossref","first-page":"CT221","DOI":"10.1158\/1538-7445.AM2020-CT221","article-title":"Abstract CT221: nivolumab (NIVO)+ ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: results from CheckMate 227","volume":"80","author":"Borghaei","year":"2020","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.004_bib0069","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006127","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2024.06.004_bib0071","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"10.1016\/j.cllc.2024.06.004_bib0072","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2024.06.004_bib0073","doi-asserted-by":"crossref","first-page":"S862","DOI":"10.1016\/j.jtho.2021.08.061","article-title":"OA09. 01 first-line nivolumab+ ipilimumab+ chemo in patients with advanced NSCLC and brain metastases: results from CheckMate 9LA","volume":"16","author":"Carbone","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.004_bib0074","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2024.06.004_bib0076","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2024.06.004_bib0077","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0078","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41392-021-00751-9","article-title":"Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.004_bib0079","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"16_suppl","key":"10.1016\/j.cllc.2024.06.004_bib0080","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1200\/JCO.2022.40.16_suppl.9027","volume":"40","author":"Zhou","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.004_bib0081","doi-asserted-by":"crossref","first-page":"e7669","DOI":"10.1371\/journal.pone.0007669","article-title":"Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer","volume":"4","author":"Roland","year":"2009","journal-title":"PLoS One"},{"issue":"10189","key":"10.1016\/j.cllc.2024.06.004_bib0082","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.cllc.2024.06.004_bib0083","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0084","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2024.06.004_bib0086","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0087","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0088","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1016709","article-title":"The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade","volume":"4","author":"Dovedi","year":"2015","journal-title":"Oncoimmunology"},{"issue":"7547","key":"10.1016\/j.cllc.2024.06.004_bib0089","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0091","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0092","first-page":"vdad018","article-title":"Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases","volume":"5","author":"Wong","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0093","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cllc.2020.10.014","article-title":"Combined immunotherapy and stereotactic radiotherapy improves neurologic outcomes in patients with non-small-cell lung cancer brain metastases","volume":"22","author":"Enright","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.06.004_bib0094","article-title":"A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation with and without immunotherapy","volume":"37","author":"Patruni","year":"2019","journal-title":"ASCO"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.004_bib0095","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0096","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0097","first-page":"1","article-title":"Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study","volume":"133","author":"Shepard","year":"2019","journal-title":"J Neurosurg"},{"issue":"24","key":"10.1016\/j.cllc.2024.06.004_bib0098","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1002\/cncr.33196","article-title":"Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases","volume":"126","author":"Qian","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2024.06.004_bib0099","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2024.06.004_bib0100","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2020.38.15_suppl.2531","article-title":"Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer: a phase I trial","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clineuro.2019.02.010","article-title":"Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy","volume":"179","author":"Weingarten","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13014-020-01644-x","article-title":"Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases","volume":"15","author":"Kowalski","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109920","article-title":"Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy","volume":"189","author":"Hall","year":"2023","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0104","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3171\/2022.7.JNS22752","volume":"138","author":"Lehrer","year":"2023","journal-title":"J Neurosurg"},{"issue":"12","key":"10.1016\/j.cllc.2024.06.004_bib0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123668","article-title":"Gamma knife radiosurgery for brain metastases in non-small cell lung cancer patients treated with immunotherapy or targeted therapy","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2024.06.004_bib0106","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/j.wneu.2020.09.082","article-title":"Impact of systemic therapy type and timing on intracranial tumor control in patients with brain metastasis from non-small-cell lung cancer treated with stereotactic radiosurgery","volume":"144","author":"Singh","year":"2020","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-023-04413-4","article-title":"Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients","volume":"165","author":"Lehrer","year":"2023","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051240","article-title":"Oncologic outcome and immune responses of radiotherapy with anti-PD-1 treatment for brain metastases regarding timing and benefiting subgroups","volume":"14","author":"Trommer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2024.06.004_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2022.9.JNS221896","article-title":"Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone","volume":"138","author":"Dohm","year":"2022","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/00207454.2021.1900843","article-title":"Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy","volume":"133","author":"Andring","year":"2023","journal-title":"Int J Neurosci"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.004_bib0111","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0112","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cllc.2021.06.009","article-title":"Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis","volume":"23","author":"Yang","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.004_bib0113","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","article-title":"Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases","volume":"132","author":"Singh","year":"2019","journal-title":"J Neurosurg"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.004_bib0114","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.radonc.2011.01.011","article-title":"Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review","volume":"98","author":"Wiggenraad","year":"2011","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.004_bib0115","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0116","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s12094-021-02588-8","article-title":"Upfront pembrolizumab as an effective treatment start in patients with PD-L1\u2009\u2265\u200950% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis","volume":"23","author":"Metro","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0117","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fonc.2018.00395","article-title":"Diagnosis and management of radiation necrosis in patients with brain metastases","volume":"8","author":"Vellayappan","year":"2018","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.004_bib0118","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1007\/s00330-020-07514-0","article-title":"Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis","volume":"31","author":"Kim","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2024.06.004_bib0120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0121","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijrobp.2020.06.057","article-title":"Predictors of adverse radiation effect in brain metastasis patients treated with stereotactic radiosurgery and immune checkpoint inhibitor therapy","volume":"108","author":"Helis","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cllc.2024.06.004_bib0122","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","article-title":"Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer","volume":"13","author":"Hubbeling","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"3, Supplement","key":"10.1016\/j.cllc.2024.06.004_bib0123","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1016\/j.ijrobp.2021.07.1547","article-title":"Prospective neurocognitive functions of patients treated with concurrent nivolumab and stereotactic brain radiosurgery for NSCLC and RCC brain metastases","volume":"111","author":"Masucci","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.004_bib0124","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.cllc.2024.06.004_bib0125","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.20.00744","article-title":"Targeting KRAS-mutant non-small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations","volume":"38","author":"Burns","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0126","doi-asserted-by":"crossref","first-page":"18174","DOI":"10.1038\/s41598-021-97566-z","article-title":"Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases","volume":"11","author":"Lauko","year":"2021","journal-title":"Sci Rep"},{"issue":"17_suppl","key":"10.1016\/j.cllc.2024.06.004_bib0127","doi-asserted-by":"crossref","first-page":"LBA9009","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9009","article-title":"Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial","volume":"40","author":"Sabari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.004_bib0128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"25","key":"10.1016\/j.cllc.2024.06.004_bib0130","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.7150\/thno.37574","article-title":"STING activation in cancer immunotherapy","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.004_bib0131","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s43018-023-00566-3","article-title":"Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation","volume":"4","author":"Wischnewski","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0132","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005924","article-title":"Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy","volume":"11","author":"Sivapalan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2024.06.004_bib0133","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0134","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41467-021-21789-x","article-title":"Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment","volume":"12","author":"Rubio-Perez","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.004_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41698-023-00413-9","article-title":"Radiomics for characterization of the glioma immune microenvironment","volume":"7","author":"Khalili","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.004_bib0136","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/j.cllc.2017.03.008","article-title":"Computed tomography features of lung adenocarcinomas with programmed death ligand 1 expression","volume":"18","author":"Toyokawa","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.004_bib0137","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.cllc.2024.06.004_bib0138","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1200\/JCO.2023.41.16_suppl.2014","article-title":"A radiomic-based predictive model of lung adenocarcinoma brain metastases and molecular subtypes","volume":"41","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0139","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.990608","article-title":"Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.004_bib0140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11060-023-04367-7","article-title":"Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer","volume":"163","author":"Mei\u00dfner","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cllc.2024.06.004_bib0141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2022.07.034","article-title":"Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review","volume":"175","author":"Ter Maat","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T18:34:36Z","timestamp":1732214076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":141,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1525730424001244"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.06.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}